Instil Bio reported its fourth quarter and full year 2025 financial results, including a net loss per share of $1.21 for Q4 2025 and $10.70 for the full year, and announced a strategic shift to focus on potential acquisitions and in-licensing opportunities. The company's cash position of $76.3 million as of December 31, 2025 is expected to fund its current operating plan beyond 2027.
Key takeaways
Reported Q4 2025 net loss per share of $1.21 and full year 2025 net loss per share of $10.70.
Reported Q4 2025 Non-GAAP net loss per share of $0.97 and full year 2025 Non-GAAP net loss per share of $6.91.
Cash, cash equivalents, restricted cash and marketable securities totaled $76.3 million as of December 31, 2025, down from $115.1 million as of December 31, 2024.
The company is pursuing potential acquisitions and in-licensing opportunities to drive its next phase of strategic development.
In January 2026, Axion Bio, a wholly owned subsidiary, discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc.